Allstate has seen its most dramatic short-interest unwind of the year in the nine days since Q2 results landed — but the analyst community that consensus note flagged as divided has only grown more fractured since.
The short-selling retreat is the headline data point this week. Short interest has collapsed 24.5% in one week, falling from roughly 7.9 million shares to 6.0 million, now sitting at just 2.3% of the free float — down from a monthly peak near 3.4%. That is the fastest multi-day unwind in the 30-day history tracked here. The borrow market reflects this: cost to borrow has dropped 40% on the week to just 0.33%, and availability has ballooned to 2,755% — meaning there are roughly 27 shares free to lend for every one currently out on loan, the loosest conditions in the 52-week dataset. Short sellers are not pressing the bear case. They are exiting it.
Options positioning tells a more complicated story. Put/call demand has moved sharply in the other direction, with the ratio climbing to 1.62 — its highest level in the past year — and running 1.6 standard deviations above its 20-day average of 1.45. In the August 6 earnings preview note, the PCR had already pulled back to 1.39; it has since surged back through the top of its annual range. That is not a squeeze-driven dynamic: with short interest this low and borrow this loose, the options hedging is more likely a reflection of valuation anxiety than directional short conviction. Investors who are still cautious are expressing it via puts, not stock borrows.
The analyst response to Q2 results was broadly constructive on targets but deeply split on direction — and that split has widened further this week. JP Morgan's Pablo Singzon raised his target to $292 and held Overweight. Piper Sandler lifted to $300, also maintaining Overweight. UBS moved its target up to $275 from $261 while staying Neutral. The bearish end of the ledger is equally fresh: Citigroup downgraded to Sell this week with a $240 target, and Wells Fargo moved to Underweight with a $250 target, even as both firms acknowledged improving fundamentals enough to raise targets from prior levels. The mean price target across the Street now stands at $274, about 5% above the current $261.41 close — modest implied upside that reflects a consensus genuinely unsure how much of the auto underwriting recovery is already in the price. Factor scores reinforce both camps: EPS surprise ranks in the 91st percentile and EPS momentum runs in the 87th percentile over 30 days, but the 12-month forward earnings growth rank sits at just 11th percentile — the Street is upgrading the past, not the future.
Insider activity has added a layer of texture. Division COO Mario Rizzo sold roughly $14.9 million of stock on August 11, and divisional President John Dugenske sold a combined $8.9 million across multiple transactions on August 7 — both sets of trades registering in the days immediately following Q2 results. These are not trivial amounts. That said, the 90-day net insider figure shows net selling of around $24.9 million by value, offset by awards that lifted net share count to a nominally positive 94,722 shares. The award-adjusted picture is less alarming than the raw sell figures, but senior executives liquidating material positions at current prices warrants attention in a week when options traders are simultaneously loading up on puts.
Allstate's closest peers offer useful context on the week's pullback. PGR fell 2.7% on the week, HIG dropped 3.7%, and CB slipped 1.9% — so the 2.1% weekly decline in ALL is roughly in line with the group rather than an idiosyncratic move. ACGL and RNR were the exceptions, each posting small gains, which suggests the drag on Allstate and its closer peers is sector-level rather than company-specific. The next scheduled catalyst is Q3 earnings on November 4. Between now and then, the most informative signal to track is whether the options PCR — now close to its annual high — begins to normalise as valuation uncertainty settles, or whether it holds elevated heading into what is historically a heavy catastrophe-loss quarter.
See the live data behind this article on ORTEX.
Open ALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
